About this release

This annual release by Public Health Scotland (PHS) follows the hepatitis C virus (HCV) surveillance report published in November 2025 and includes the most up-to-date surveillance data through December 2025, except for data from the HCV clinical database, which is reported by financial year up to the end of March 2026. The report outlines Scotland’s progress toward achieving both national and World Health Organization (WHO) hepatitis C elimination targets described in the Background section below.

Main points

Progress against targets

Public health surveillance data indicate that Scotland continues to make substantial progress towards WHO hepatitis C elimination, including achieving several impact and programmatic targets:

  • HCV-related mortality: hepatitis C-related mortality remained below the WHO target of ≤2 deaths per 100,000 population annually in 2025, at 1.03 deaths per 100,000 among those ever chronically infected and 0.22 per 100,000 among those currently chronically infected.
  • Treatment coverage: by March 2026, 86% of people last known to have a chronic HCV infection had received treatment, exceeding the WHO target of 80%.
  • Harm reduction coverage: coverage of opioid agonist therapy (OAT) among people who use opioids remained high at 76% in 2024, exceeding the WHO target of 40%. Needle and syringe provision also exceeded the WHO target of 200 sterile items per person who injects drugs annually by 2025, with a median of 260 sterile items distributed per person based on the latest Needle Exchange Surveillance Initiative (NESI) survey, conducted from November 2022 through to December 2023, although this remained below the more ambitious 2030 target of 300 items per person annually.

Marked progress has been made towards hepatitis C elimination, but important gaps remain in achieving key WHO and Scottish Government (SG) targets:

  • Severe liver disease: in 2025, the SG target was met for HCV-related hepatocellular carcinoma (HCC) admissions (8) but not for HCV-related decompensated cirrhosis (DC) admissions (13) or deaths (12), both of which remained above the target threshold of fewer than 10 annual events among people with chronic HCV infection at the time of admission or death.
  • Incidence and prevalence: estimated HCV incidence among people at risk, based on model-based analysis, fell to 3.4 per 100 person-years by 2022/23, alongside a 59% reduction in chronic HCV prevalence among people who inject drugs since 2015. However, neither has yet reached the WHO targets of ≤2 per 100 person-years and an 80% reduction in prevalence, respectively.
  • Diagnosis coverage: among people who attended drug services, an estimated 83% of those who had chronic HCV infection had been diagnosed by March 2024, approaching the WHO target of 90%, although diagnosis coverage among people not captured through these services is unknown. Among people who inject drugs, 74% of those living with, or previously had, chronic HCV had been diagnosed in 2022/23.
  • Testing coverage: a record 158,270 individuals were tested for HCV overall in Scotland in 2025 but testing coverage in prisons and Alcohol and Drug Recovery Services (ADRS) remained below the incremental SG targets for financial year (FY) 2025/26. In 2025, 28% of prison entrants were tested within six weeks of prison entry and 37% of people prescribed OAT were tested in the previous year. SG targets for 2027/28 are 75% and 80% respectively.
  • Diagnosis of first infection: despite record testing levels overall, first infection HCV diagnoses fell from 1,351 in 2024 to 1,129 in 2025. These figures do not include diagnoses of HCV reinfection.
  • Treatment uptake: in FY 2025/26, 1,191 individuals initiated HCV treatment, representing 68% of the SG minimum national annual target of 1,750 treatment initiations. Among those diagnosed between January and December 2024, 48% initiated treatment within three months, increasing to 65% within six months and 75% within 12 months, with six NHS Boards exceeding the Scotland figure across all three time periods.

Delivery strategy

The WHO global target is to eliminate hepatitis C as a public health threat by 2030. Achieving elimination should be viewed as an ongoing process rather than a one-off milestone. Progress against the WHO targets must be sustained and supported by systems that can adapt to changing patterns of transmission, drug use, service delivery and population need.

Testing, diagnosis, treatment and prevention should therefore be embedded in routine practice and supported by robust surveillance capable of identifying reductions in testing or case detection at an early stage.

Scotland has made substantial progress towards hepatitis C elimination, including increased treatment uptake and reductions in HCV-related morbidity and mortality. However, further progress is needed to reduce severe liver-related outcomes and new infections.

It is necessary to increase testing and diagnosis among people who inject drugs, people in prisons and among populations that are not engaged with drug treatment and to ensure that people diagnosed with HCV start treatment promptly.

To achieve WHO and SG elimination goals and ensure that people affected by HCV infection benefit from high-quality prevention, treatment and care, continued action is required in the following areas:

  • Primary prevention
    • Maintain a high coverage of opioid agonist therapy and needle and syringe provision among people who inject drugs.
    • Address inequalities and stigma and respond to evolving patterns of risk.
  • Secondary prevention
    • Integrate blood-borne virus testing across HCV, HBV and HIV programmes.
    • Increase HCV testing and diagnosis among people with a history of injecting drug use and people in prisons and reduce variation in testing across ADRS, prisons and other settings.
    • Strengthen prevention and detection of HCV reinfection, particularly in populations and settings at higher risk of transmission.
    • Ensure high treatment coverage among people diagnosed with chronic HCV infection.
    • Reduce variation across NHS Boards in the time from diagnosis to treatment initiation.
    • Identify and learn from missed opportunities for earlier prevention, diagnosis and treatment through reviews of late diagnoses and HCV-related harm.
  • Tertiary prevention
    • Reduce HCV-related morbidity and mortality through appropriate follow-up and management of people with advanced liver disease.
  • Monitoring and evaluation
  • Continue monitoring testing rates and time from HCV diagnosis to treatment initiation to improve case finding and identify and address delays in access to treatment.
  • Establish HCV reinfection surveillance and maintain monitoring and modelling of HCV prevalence, incidence and reinfection to inform prevention and elimination efforts.
  • Support local and national action through timely access to data and intelligence.

The Scottish Health Protection Network supports national and local partners in delivering and sustaining these actions.

Background

Hepatitis C is a bloodborne infection caused by the hepatitis C virus (HCV) and chronic infection can result in serious liver disease such as HCC and DC. Acute infection is often asymptomatic, although some people may experience symptoms such as malaise, fatigue, nausea and jaundice. Hepatitis C can be cured in >90% of cases using direct-acting antiviral (DAA) treatment, which is accessible for free within NHS Scotland. Further information on hepatitis C is available on Hepatitis C | NHS inform.

In 2016, WHO launched its Global Health Sector Strategy on Viral Hepatitis, setting the goal of eliminating viral hepatitis as a public health threat by 2030. On 31 July 2019, SG committed to eliminating hepatitis C virus (HCV) as a major public health concern in Scotland. In July 2026, Public Health Scotland (PHS) published the second iteration of the Data Monitoring Plan (DMP), which incorporates indicators to monitor progress on WHO hepatitis C elimination targets. These include:

  • impact targets, which define progress on infection and disease levels needed to achieve elimination as a public health concern, including:
  • reducing new HCV infections by 80%, to fewer than 5 per 100,000 population annually and no more than 2 per 100 people who inject drugs annually;
  • reducing HCV-related mortality by 65%, to 2 or fewer deaths per 100,000 population by 2030.
  • programmatic targets, which relate to the interventions required to achieve elimination, including:
  • diagnosing 90% of people living with HCV infection;
  • treating 80% of those diagnosed;
  • achieving strong harm-reduction coverage, including the distribution of at least 300 sterile needles and syringes per people who inject drugs per year and OAT coverage of at least 40% among people who inject drugs by 2030.

All WHO elimination targets must be achieved, monitored and sustained for a minimum of two consecutive years.

In addition to the WHO elimination framework, SG established national targets to support the definition and measurement of HCV elimination in Scotland. These included reducing the number of people living with chronic HCV infection to 5,000 or fewer and reducing HCV-related morbidity and mortality to fewer than 10 new presentations with DC or HCC and fewer than 10 deaths due to DC or HCC, per year by 2024/25. Operational targets were also set to support progress towards elimination, including annual national and local targets for HCV treatment initiation, with a minimum national target of 1,750 treatment initiations for FY 2025/26, and new testing targets in key settings and populations (prisons and people receiving OAT) from 2025. These included testing at least 75% of individuals in prison within six weeks of prison entry (admission or transfer) and at least 80% of individuals prescribed OAT in the previous year by 2027/28.

Further information

The next release of this publication will be in 2027/28 date to be confirmed.

General enquiries

If you have an enquiry relating to this publication, please contact Duncan McCormick at phs.bbvsti@phs.scot.

Media enquiries

If you have a media enquiry relating to this publication, please contact the Communications and Engagement team.

Requesting other formats and reporting issues

If you require publications or documents in other formats, please email phs.otherformats@phs.scot.

To report any issues with a publication, please email phs.generalpublications@phs.scot.

Older versions of this publication

Versions of this publication released before 16 March 2020 may be found on the Data and Intelligence, Health Protection Scotland or Improving Health websites.

Last updated: 11 November 2026